Supriya Lifescience Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Supriya Lifescience Ltd. on BSE

Load latest

Supriya Lifescience Ltd.

27 May 2025

681.80

4.05%

Corp. Action

Supriya Lifescience Ltd - 543434 - Corporate Action-Board to consider Dividend

BSE India

Board recommended Final Dividend at its meeting held on May 27, 2025

pdf

Supriya Lifescience Ltd.

27 May 2025

681.80

4.05%

Result

Supriya Lifescience Ltd - 543434 - Audited Financial Result For Quarter And Year Ended On March …

BSE India

Audited Financial Results for the year ended March 31, 2025

pdf

	Mar 2025	Dec 2024	Mar 2024	Change QoQ%	Change YoY%
Total Revenue Qtr	187.08	187.75	160.36	-0.4%	16.7%
Operating Profit Qtr	67.58	65.95	55.50	2.5%	21.8%
Net Profit Qtr	50.38	46.78	36.93	7.7%	36.4%
Earning Per Share Adjusted latest Qtr	6.26	5.81	4.59	7.7%	36.4%

* Standalone data

Detailed Results

Supriya Lifescience Ltd.

27 May 2025

681.80

4.05%

Board Meeting

Supriya Lifescience Ltd - 543434 - Board Meeting Outcome for Outcome Of Board Meeting Held On …

BSE India

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held on Tuesday, May 27, 2025, inter-alia considered and approved the following: 1. Audited Financial Results 2. Dividend 3. Appointment of Secretarial Auditors The Meeting of the Board of Directors of the Company commenced at 03:30 p.m. and concluded at 04.10 p.m. Kindly take the above information on your records.

pdf

Supriya Lifescience Ltd.

21 May 2025, 05:18PM

681.80

4.05%

Investor Presentation

Supriya Lifescience Ltd - 543434 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that an earnings call will be held on Wednesday, May 28, 2025 at 11.00 A.M. IST to discuss operational and financial performance of the Company for the quarter and year ended March 31, 2025. The invite giving requisite details including the pre-registration link and dial-in details is enclosed herewith. The investor presentation shall be shared with the Exchanges separately. Kindly take the information on record.

pdf

Supriya Lifescience Ltd.

20 May 2025, 05:16PM

681.80

4.05%

Board Meeting

Supriya Lifescience Ltd - 543434 - Board Meeting Intimation for Audited Financial Results Of The Company …

BSE India

Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2025 ,inter alia, to consider and approve In terms of Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this to inform you that a meeting of the Board of Directors of the Company will be held on Tuesday, May 27, 2025, inter alia to: 1. Consider and approve the Audited Financial Results of the Company for the quarter and year ended March 31, 2025. 2. Recommend dividend, if any, on the Equity Shares of the Company for the financial year ended March 31, 2025. This is to further inform you that in accordance with the Company's Code of Conduct for Prevention of Insider Trading, the ''Trading Window' for dealing in the securities of the Company by Designated Persons and their immediate relatives is closed from April 1, 2025, till 48 hours after declaration of Audited Financial Results on May 27, 2025. Kindly take the above information on your records.

pdf

Supriya Lifescience Ltd.

28 Apr 2025

681.80

4.05%

Corp. Note

Supriya Lifescience Ltd - 543434 - Format of the Initial Disclosure to be made by an …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanySupriya Lifescience Ltd 2CIN NO.L51900MH2008PLC180452 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY A+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Prachi Sathe Designation: Company Secretary and Compliance Officer EmailId: cs@supriyalifescience.com Name of the Chief Financial Officer: Krishna Raghunathan Designation: Chief Financial Officer EmailId: cs@supriyalifescience.com Date: 28/04/2025 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf